FRANKFURT (dpa-AFX) - Fresenius shares successfully bucked the negative trend in the DAX on Tuesday. The Bad Homburg-based company's shares climbed a good 3.5 percent to their highest level for around two months.

The evening before, Fresenius announced the US market launch of the biosimilar Tyenne. This is a copycat product of the previously patent-protected antibody Tocilizumab against various autoimmune diseases.

According to DZ Bank expert Sven Kürten, the market launch comes somewhat earlier than he had expected. The news shows that Fresenius is still on a very good path. However, he does not see any direct impact on his profit forecasts./ag/jha/